An antibody deal between Genmab A/S and F. Hoffmann-La Roche Ltd. may have raised a few eyebrows last week among those who follow the spinout of Medarex Inc. (MEDX, Princeton, N.J.).

Genmab (CSE:GEN; NMarkt:GE9D, Copenhagen, Denmark) uses HuMAb and UltiMAb transgenic mouse technology licensed from MEDX to generate human monoclonal antibodies against targets it in-licenses or